Home › Trial NCT00082095
To Compare Treatment With Doxorubicin or Capecitabine for Metastatic Breast Cancer in Women 60 Years and Older
- Trial IDNCT00082095
- StatusTerminated
- PhasePhase 3
- Study typeInterventional
- SponsorJohnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Enrollment62
- Start date2004-04
- ConditionsMetastatic Breast Cancer
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.